BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyGlobeNewsWire • 04/17/24
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/26/24
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 02/26/24
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) TreatmentGlobeNewsWire • 02/23/24
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingGlobeNewsWire • 02/05/24
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to ProfitabilityGlobeNewsWire • 01/05/24
BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)GlobeNewsWire • 12/19/23
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in ArgentinaGlobeNewsWire • 11/29/23
BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)GlobeNewsWire • 11/10/23
BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 MonthsGlobeNewsWire • 11/03/23
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®GlobeNewsWire • 11/03/23
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/02/23
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & ImmunologyGlobeNewsWire • 10/27/23
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013GlobeNewsWire • 10/26/23